The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, temozolomide CAPTEM)—First results for pancreas and updated midgut neuroendocrine tumors (pNETS, mNETS).
 
Nick Pavlakis
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Merck KGaA; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Research Funding - Bayer (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Roche
 
David Turner Ransom
Research Funding - Ipsen (Inst)
Travel, Accommodations, Expenses - Ipsen; Novartis
 
David Wyld
Consulting or Advisory Role - Ipsen
Speakers' Bureau - Ipsen
Research Funding - Ipsen (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Ipsen; Novartis
 
Katrin Marie Sjoquist
Honoraria - AMGEN; Bristol-Myers Squibb; Merck; SERVIER
Research Funding - Bayer (Inst)
 
Rebecca Asher
No Relationships to Disclose
 
Val Gebski
No Relationships to Disclose
 
Kate Wilson
No Relationships to Disclose
 
Andrew Ddembe Kiberu
No Relationships to Disclose
 
Matthew E. Burge
Stock and Other Ownership Interests - Bristol-Myers Squibb; coclear; CSL Limited; Gilead Sciences; pfizer
Honoraria - Amgen; Merck KGaA; Merck Sharp & Dohme; Roche; SERVIER
Consulting or Advisory Role - Amgen; ipsen; Roche
Patents, Royalties, Other Intellectual Property - funding for an investigator initiated prospective trial (Inst)
Travel, Accommodations, Expenses - Amgen; Roche; Roche
 
William Macdonald
No Relationships to Disclose
 
Paul Roach
No Relationships to Disclose
 
David A. Pattison
No Relationships to Disclose
 
Patrick Butler
No Relationships to Disclose
 
Timothy Jay Price
Consulting or Advisory Role - Amgen; Merck Serono (Inst); Roche (Inst)
Research Funding - AMGEN (Inst)
Travel, Accommodations, Expenses - Amgen
 
Michael Michael
Consulting or Advisory Role - Ipsen; Merck
Travel, Accommodations, Expenses - Novartis
 
Benjamin James Lawrence
Employment - Canopy Cancer Care
Leadership - Canopy Cancer Care
Stock and Other Ownership Interests - Canopy Cancer Care
 
Dale L. Bailey
No Relationships to Disclose
 
Simone Leyden
No Relationships to Disclose
 
John Raymond Zalcberg
Stock and Other Ownership Interests - Aimmune; Alnylam; Biomarin; Bluebird Bio; Cochlear; CSL Limited; Dova Pharmaceuticals; GW Pharmaceuticals; Juno Therapeutics; Kiadis Pharma; Kite, a Gilead company; Sage Therapeutics; TherapeuticsMD; Vertex
Honoraria - Gilead Sciences; Halozyme; Merck Serono; pfizer; Specialised Therapeutics; Targovax
Consulting or Advisory Role - Halozyme; Lipotek; Merck Serono; Merck Sharp & Dohme; Pfizer; Sirtex Medical; Targovax
Research Funding - AstraZeneca (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono (Inst); Pfizer (Inst); Roche (Inst); Specialised Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Deciphera; Merck Serono; Merck Sharp & Dohme
 
J. Harvey Turner
No Relationships to Disclose